Bought some of these this morning as Instiutional interest as really boiled up over them. They have just announced a very positive deal and from what I can see theres quite a lot of news flow in the pipeline to keep this one going throughout the rest of the year. Its highly speculative but give me a Bio company that isnt.

Heres just a little historical detail about the company from the last results prelims 31/12/2004.

HIGHLIGHTS

Listing on London Stock Exchange raised 55 million
Kerraboot(R) received UK Drug Tariff Listing at a reimbursement price
of 14
Kerraboot(R) UK sales showed steady upward trend in first six months
of primary care promotion
Second safety and efficacy study for Cerepro(TM) showed mean patient
survival time increased by 80% in malignant glioma
Trinam(R) received Orphan Drug Designation in the EU
First international out-licensing deal signed with Teva Medical for
Kerraboot(R) in Israel
EG005 Phase II in lipodystrophy completed enrolment
Finnish manufacturing facility received Good Manufacturing Practice
certification (cGMP)
Named patient supplies of Vitor(TM) made available at request of
investigators for patients completing Phase III study
Cash of 47 million at 31 December 2004

POST YEAR-END EVENTS

Patent for Trinam(R) granted by European Patent Office

Dr Nigel Parker, CEO of Ark, commented:

'We made substantial progress in all aspects of our business in 2004 and
demonstrated that we are delivering on key milestones during our first year as a
publicly quoted company. Our progress to date supports our belief that we are
well placed to achieve our goal of becoming one of a successful new breed of
diversified healthcare companies servicing areas of high clinical need in
hospital and specialist medicine.'

ARKs History

Ark Therapeutics Group plc

Ark is a specialist healthcare group (the 'Group') with one marketed product and
three further lead products in late stage clinical development. Capitalising on
over ten years of research in vascular biology and gene-based medicine, Ark has
a balanced product portfolio targeted at specific unmet clinical needs within
vascular disease and cancer. These are large and growing markets, where
opportunities exist for effective new products to generate significant revenues.

Ark's products are sourced from related but largely non-dependent technologies
within the Group and have been selected to enable them to be taken through
development within the Company's own means and to benefit from Orphan Drug
Status and/or Fast Track Designation, as appropriate. This strategy has allowed
the Group to retain greater value and greater control of clinical development
timelines, and to mitigate the risks of dependency on any one particular
programme or development partner. Ark has secured patents or has patent
applications pending for all its lead products in principal pharmaceutical
markets.

Ark has its origins in businesses established in the mid-1990s by Professor John
Martin and Mr Stephen Barker of University College London and Professor Seppo
Yla-Herttuala of the AI Virtanen Institute at the University of Kuopio,
Finland, all of whom continue to play leading roles in the Company's research
and development programmes.

You can find full details of the last results here, http://www.uk-wire.com/cgi-bin/articles/200503100700205623J.html

Worth a punt I feel but as I have previously stated its high risk.

DYOR.

cheers GF.

Solid looking chart.



cheers GF

From Pat Lays small cap column yesterday................

One to watch out for

Ark Therapeutics
The fact that Boehringer Ingelheim has signed a deal with Ark Therapeutics that gives it freedom to act under some of Ark's patents, was 'totally unexpected' says Erling Refsum at Nomura International. He has upgraded his estimates for the next three years and says the shares are a 'strong buy'.

cheers GF.

And from CityWire today....................

Shrewd Tip: Top investors jump on rising biotech
Published: 07:09 Friday 08 April 2005


Two highly-rated smaller companies managers and a gaggle of analysts are betting on an emerging healthcare biotech business, which surprised with a major deal last week and looks set for further good news.

Leading Citywire BrainsTrust constituent Ark Therapeutics (AKT) has attracted the attention of Framlington's AAA-rated Roger Whiteoak and New Star's rising star Jamie Allsopp in recent weeks as well analysts from Numis, Nomura and Credit Suisse First Boston.

Whiteoak added 150,000 shares to the holding of his Framlington UK Smaller Companies fund (Framlington UK Smaller Companies Acc) in the middle of last month to increase its holding to 1 million shares. Whiteoak also holds 2.14 million shares in the Throgmorton investment trust (THRG) .

He first bought last September when the share price was about 71p, it has since risen to 119p at last night's close, up 2p on the day.

New Star's Allsopp, who was the top performing UK All Companies manager over the 12 months to January, is also a big fan. He has been running the New Star Hidden Value fund (New Star Hidden Value B) since October 2003 and first got into Ark shortly after its float in April last year. He added 20,000 shares in early March to give his fund 374,100 shares.

Allsopp told Citywire: 'I saw Ark pre-float and really liked it but didn't invest but when its share price fell and it became absurdly cheap I did and now I'm absolutely delighted with it.'

He pointed out its Kerraboot product for foot and leg ulcers is already on the market and although it may be a slow burner has the potential to produce significant revenue. It also has the Cerepro treatment for brain tumours for which it has applied for marketing authorisation. Two further products, muscle wasting treatment Vitor and Trinam, are not included in any analysts forecasts and therefore investors get them for free. If Vitor proves to be as promising analysts suspect it may well be fast-tracked to approval without the need for a phase III trial.

Allsopp said: 'Some people say a diverse portfolio is a hindrance but I think it is a positive.'

On top of this solid portfolio of products Ark signed a deal last week with German pharmaceutical giant Boehringer granting the German company exclusive rights to Ark's intellectual property in relation to therapies for cardiovascular ailments. The deal involves an upfront payment and various milestone payments going forward followed by royalties on any product which evolves.

Considering Ark has very little research and development costs now as most of its products are in later stage trials the majority of any payments it receives will go straight to the bottom line.

Analysts became very excited following the Boehringer deal, Numis's Robin Gilbert and Brett Pollard reiterated their buy recommendation with an increase in the price target from 133p to 145p. CSFB has gone further, increasing its price target to 163p today.

CSFB reckons Boehringer will pay 1 million upfront, to be booked this year with further payments of about 8.5 million contingent on achieving patents and approvals.

Nomura's Erling Refsum has a strong buy recommendation. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'

Last year losses widened by 60% to 14 million despite a rise in turnover. With some cash left over from its float and Kerraboot beginning to bring in some revenues Ark is in a strengthening position. As yet there is no prediction for profitability but the Boehringer deal brings it a step closer.

On Thursday Ark announced the appointment of Dr David Eckland to replace Dr Alan Boyd who is going part-time for personal reasons. Eckland, who joins from Japan's Takeda, will be head of research and drug development, he previously held senior positions at Glaxo Wellcome.

With top investors and analysts leaping on the stock its share price growth since the turn of this year has seen it had almost 50% and although this may slow a little a good pipeline of newsflow should keep Ark in investors' minds throughout 2005. It may be a long term bet but investors should consider Ark a buy for risk-takers.

cheers GF.

This article although a week old from CityWire gives a bit more depth to the license deal..................

Ark floats higher on Boehringer deal

By: Graeme Davies, Investment Correspondent


Ark Therapeutics, a leading Citywire BrainsTrust Constituent, is in demand after signing an unexpected but potentially money-spinning deal with German pharmaceutical giant Boehringer.

Boehringer has been granted exclusive rights to Ark's (AKT) intellectual property in relation to therapies for cardiovascular problems. Boehringer is undertaking major clinical trials into cardiovascular disease and repeat strokes. Boehringer is a private German company listed among the top 20 pharmaceutical companies worldwide.

The deal involves a 'material upfront payment on signing and several multi million Euro payments expected over the next few years on the achievement of certain pre-defined milestones', according to today's statement. Following the successful completion of any clinical trials Ark will also receive a royalty on sales of any resultant product.

Analyst Erling Refsum of Nomura has reiterated a strong buy recommendation for Ark. He estimates the upfront payment could be about 1 million and the milestones could add up to 50 million. He said: 'The deal was totally unexpected, generates cash for minimal expenditure and opens the door to other companies following suit.'

Numis' Robin Gilbert and Brett Pollard have a buy recommendation and have increased their price target from 133p to 145p. They reckon the total package could be worth 20 million and could lead to similar deals in future. Numis said: 'Ark has no R&D commitment to this deal and thus cash received will fall straight to the bottom line, or at least offset its R&D expenditure elsewhere.'

Investors have reacted positively, sending Ark 6.5p higher to 116p. Ark ranks 25th in the Citywire BrainsTrust Small Cap index, an analysis of the most popular stocks held by the UK's best performing smaller companies managers. Stocks are listed in terms of how overweight managers are compared with the stock's weighting in the FTSE SmallCap, excluding investment trusts.

Ark has targeted the treatment of vascular conditions as the population ages and the medical community searches for ever more effective treatment of vascular problems. Chief executive Nigel Parker today opened up the possibility of further deals: 'Whilst Boehringer Ingelheim is the first to acknowledge the importance of Ark's discoveries in these areas, Ark may grant further licences in the future to other companies.'

cheers GF.

Buys flowing in now.

cheers GF.

Ready to tick up.

cheers GF.

Quite like the look of this one GF,, im in , have you only bought in recently in the 120's...JB

Yes just this morning Jimmy. Just in profit and its looking good for another move up.

cheers GF.

Just added again spread moved into only 1/2p. Could have the tick up I was talking about.

cheers GF.

A good day for my new signing.

cheers GF.

Yes im in at 122.4p, looking back at shares mag they had a lot of positive press earlier this year.Cheers GF, might be another good one..JB..

I`m in today at 122.5. Looks good.

I'm in aswell great promise here, good summary GF and good luck all holders

Wellcome aboard Guys Im hoping that the newsflow will lead to upgrades as we go through the year. Present broker targets I feel and they more or less say so aswell do not reflect the potential of this one.

PLease remember patience is the key, overnight gains are not made in any solid company.

cheers GF.

Nice lift here this morning, didn't have to wait long ..!

Chiva

Yup moving along nicely on a rotten day over all.

cheers Gf.

Ticked up again over the lunch period.

cheers GF.

Pleased with this one GF,

Missed this last week Jimmy, I must be slipping. From the Investors Chronicle.

Tip Updates:
*Sell Cosalt (CSLT.L).
*Buy Speedy Hire (SDY.L) and Ark Therapeutics (AKT.L).
*Hold AttentiV Systems (ATN.L).
*African Diamonds (AFD.L) fairly priced.

cheers GF.

Looks ready to tick up.

cheers GF.